Paradoxically, the isoform of RPL22L1 that is suppressed by WIN site blockade, RPL22L1a, is linked in glioblastoma cells to ribosome function, not splicing (Larionova et al., 2022), while the splicing-relevant RPL22L1b isoform is resistant to WINi. The gene discussed is FOXM1; the disease is glioblastoma.